Cyberounds Logo
August 11, 2020 | LOGIN | REGISTER | HELP | 

email a friend print Bookmark and Share
NMDA Receptors and Ischemic Brain Injury
CME credit is no longer available for this conference.
Josef Anrather, V.M.D., and Costantino Iadecola, M.D.

Dr. Anrather is Assistant Professor and Dr. Iadecola is the G. C. Cotzias Distinguished Professor in the Department of Neurology and Neuroscience at Weill Cornell Medical College.

Both report no commercial conflict of interest.

This activity is made possible by an unrestricted educational grant from Forest Laboratories.

Release Date: 03/09/2004
Termination Date: 03/09/2007

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Learn about the neurotoxicity associated with NMDA receptors and related mechanisms
  • Learn about the role of NMDA-induced neurotoxicity in ischemic brain injury
  • Understand the therapeutic potential of NMDA receptor inhibitors in ischemic stroke.

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Please click below to accept the terms of this CME activity